The advent of microsurgical tissue transfer including replantation greatly has expanded the
scope of reconstructive surgery. There are few recent innovations in anticoagulation …

Clinical outcomes of 1,478 danaparoid treatment case reports for HIT (involving 1,418
patients) treated between 1982 and mid-2004 are analysed. Treatment in 1,291 episodes …

Background: Heparin‐induced thrombocytopenia (HIT) is a prothrombotic adverse drug
reaction caused by heparin. As thrombocytopenia is common in hospitalized patients …

Heparin-induced thrombocytopenia (HIT) is caused by antibodies against a “self” protein—
platelet factor 4—bound to heparin. We observed an overrepresentation of the female …

Heparin-induced thrombocytopenia (HIT) has a distinct clinical profile and unique
pathogenesis. It is caused by platelet-activating IgG antibodies that recognize …

Background: Thrombocytopenia is a common occurrence in critical illness, reported in up to
41% of patients. Systematic evaluation of thrombocytopenia in critical care is essential to …

Objective: TO review literature evaluating the use of fondaparinux for thromboembolic
treatment and prophylaxis in patients with heparin-induced thrombocytopenia (HIT). Data …

INTRODUCTION: Randomized controlled trials evaluating treatment of acute, transient, but
uncommon diseases are difficult to perform. The prothrombotic adverse drug reaction …

Heparin-induced thrombocytopenia (HIT), a well-known side effect of heparin therapy,
occurs with an incidence of 1–2% in certain pediatric patient groups. In affected children, HIT …

Introduction Heparin-induced thrombocytopenia (HIT) is described as a decrease in platelet
count associated with heparin administration and is an immune-mediated adverse drug …